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Abstract. In the Milan area (Northern Italy), we identified a
family characterized by a high prevalence of ovarian and breast
cancer cases (5 out of 6 subjects, over 3 generations), and a
predominant prevalence of ovarian lesions (4 out of 5 patients).
Analysis of BRCA1 and BRCA2 genes allowed the identi-
fication of the missense c.190T>C mutation in codon 64
(Cys64Arg) of BRCA1. The aims of the present investigation
were to characterize the functional implications of the
c.190T>C mutation at the molecular level, and to search
whether additional polymorphisms might be linked to the
peculiar phenotypic features observed in the Italian pedigree.
Molecular modelling studies suggested that substitution of
the cysteine 64 with an arginine likely disrupts the architecture
of the BRCA1 RING finger domain, responsible for the
interaction with BARD1, essential for the tumor-suppressor
activity of the BRCA1-BARD1 complex. By splicing site
information analysis, exonic splicing enhancer site character-
ization, and analysis of transcript fragment length and
sequence, we showed that the c.190T>C mutation was able to
modulate the splicing of exon 5 in a fashion opposite to the
c.190T>G transversion, responsible for the functionally-related
Cys64Gly amino acid substitution. Genotyping of BRCA1
and BRCA2 in the Italian family revealed the presence of two
significant polymorphisms: the cancer-associated c.2612C>T
SNP in BRCA1, and the c.-26G>A SNP in the BRCA2 gene,
acting as an ovarian cancer risk modifier in carriers of
deleterious BRCA1 mutations. Analysis of these SNPs in a
genotypically-unrelated Polish family, characterized by
prevalent breast neoplasms in carriers of the c.190T>C
mutation, revealed a genetic profile consistent with the
hypothetic role of both polymorphisms.
Introduction
Hereditary breast cancer accounts for 5-10% of all breast
cancers worldwide. Prevalence of BRCA1 and BRCA2
mutations among high-risk cancer patients may vary by
ethnicity, study inclusion criteria and mutation detection
techniques. Since their early characterization, inherited
BRCA1 mutations were found to be responsible for ~45% of
inherited early-onset breast cancers, and for >80% of inherited
breast and ovarian cancers (1). In Europe, BRCA1 mutation
frequencies in breast cancer populations show considerable
variability and range between 0.4% in Finland and 7% in
Sweden (2). Meta-analytic mean cumulative cancer risks for
mutation carriers at age 70 years are 57% for BRCA1 and 49%
for BRCA2 mutation carriers; ovarian cancer risk is 40% for
BRCA1 and 18% for BRCA2 mutation carriers (3). In Italy,
breast cancer penetrance, estimated in a series of 568 families,
was found to be 27% at age 50 and 39% at age 70 in BRCA1
mutation carriers, and 26% at age 50 and 44% at age 70 in
BRCA2 mutation carriers (4). Ovarian cancer penetrances in
Italy were estimated to be 14% at age 50 and 43% at age 70 in
BRCA1 mutation carriers, and 3% at age 50 and 15% at age 70
in BRCA2 mutation carriers (4).
BRCA1 is a gene with a coding sequence spanning over
23 exons, including the large exon 11, that holds more than
half of the coding potential of the gene (5). The major BRCA1
product comprises 1863 amino acids and can be subdivided
into three major domains: a RING domain adjacent to the
amino-terminus, tandem-repeated C-terminal BRCT domains,
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and a central domain, including the large region encoded by
exon 11.
The function of the poorly conserved central domain is not
fully understood, although some evidence suggests interaction
with RAD51 (6). The structure of BRCT motifs is similar to
C-terminal domains found in a number of proteins involved
in cell cycle checkpoints and DNA repair (reviewed in ref. 7).
BRCT motifs were shown to activate gene transcription
when linked to a DNA-binding domain (8).
The RING domain is probably the better-characterized
structure of BRCA1. It encompasses amino acid residues
24-64 and contains a Cys3-Hys-Cys4 (C3HC4) motif, which
has been shown to allow interaction with proteins involved in
cell-cycle regulation, such as cyclins and cyclin-dependent
kinases (9), and with estrogen receptors (10). A major binding
partner is the BRCA1-associated RING domain protein 1
(BARD1). Originally identified due to its interaction with the
RING domain of BRCA1 (11), BARD1 is required for S phase
progression, contact inhibition and normal nuclear division.
BRCA1 acquires significant ubiquitin ligase activity when
bound to BARD1 as a RING heterodimer, and catalyzes Lys-
6-linked polyubiquitin chains, which are recognized in vitro
by the 26S proteasome for deubiquitination as opposed to
degradation (12).
Pathogenic alterations in BRCA1 include mutations in the
regulatory regions of the gene, splice site mutations, nonsense/
frameshift/missense mutations, and large chromosomal
rearrangements, estimated to account for ~19% of all BRCA1
mutations in Italian patients (13).
In Northern Italy, we identified a family characterized by
a high prevalence of neoplasia: of a total of 6 women in a 3-
generation maternal lineage, 4 were affected by ovarian
cancer, and one by early-onset bilateral breast cancer
associated with ovarian dysplasia and abnormalities. The
only non-diseased subject showed breast dysplastic lesions.
In two patients belonging to the youngest generation and
treated with a modern approach, a good prognosis and long-
term survival was observed. Although family history was
collected at diagnosis or hospitalization, patients were not
subjected to genetic analysis, nor were treated as members of
a HBOC pedigree.
To identify the molecular determinants of the hereditary
breast and ovary cancer (HBOC) syndrome in this family, we
analyzed the BRCA1 and BRCA2 genotypes of one patient,
and extended to the rest of the family and to a family from
Poland without Italian ancestry some observations about the
peculiar genotype/phenotype of this family. In addition, we
performed a molecular study, both in vitro and in silico, to
characterize at the functional level the gene and protein
alterations associated with the c.190T>C (Cys64Arg) mutation.
Materials and methods
Detection of BRCA1 and BRCA2 mutations and polymorphisms
High-resolution melting analysis. DNA was extracted from
peripheral blood leukocytes of Patient 1 (Fig. 1), and the entire
coding sequence and exon-intron boundaries were amplified
using the polymerase chain reaction (PCR). Thirty-six PCR
products (size range: 150-437 bp for BRCA1) and 49 PCR
products (179-500 bp for BRCA2) were amplified (14). PCR
was performed in 10 μl reaction mixture containing template
DNA, dNTPs (Roche, Mannheim, Germany), FastStart Taq
DNA Polymerase (Roche), fluorescent dye LCGreen Plus
(Idaho Technology) and forward and reverse primers for each
gene segment, in Roche LightCycler capillaries and amplified
in an adapted RapidCycler2 instrument (Idaho Technology).
PCRs were performed using appropriate sets of primers as
described (14), with slight modifications.
PCR conditions were optimized to Tm between 49 and
68˚C for each segment. After 40 cycles of amplification, PCR
products underwent an additional cycle of 1 min at 98˚C,
followed by 5 min at 40˚C to promote heteroduplex formation.
Reaction products were then transferred to a high-resolution
melter instrument (HR-1, Idaho Technology) for high-
resolution melting and curve analysis. Samples were melted
at 0.2˚C/sec ramp rate. Melting profiles were analyzed with the
HR-1 software using fluorescence normalization, temperature
shift and conversion to difference and derivative plots. Frag-
ments with melting patterns different from the wild-type were
sequenced to determine the exact sequence alterations.
Nucleotide numbering was according to BIC database,
where position 1 represents the first nucleotide of exon 1.
Reference sequences used were NG_005905.1 for BRCA1, and
NW_001838072.1 for BRCA2.
Before sequencing, PCR products were purified with
ExoSAP-IT (USB, Cleveland, USA), and then sequenced
in both directions using the Big Dye terminator 1.1 cycle
sequencing kit (Applied Biosystems, Foster City, USA).
Sequencing analysis was performed on an automatic sequencer
ABI PRISM 310 genetic analyzer (Applied Biosystems).
RNA-based sequencing. In the Polish pedigree, detection
of the c.190T>C mutation in BRCA1 was performed by
sequencing RT-PCR products, amplified from RNA purified
from peripheral blood lymphocytes of patients and relatives,
as previously described (15).
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Figure 1. Schematic pedigree representing the Italian HBOC family
described in this study. The abbreviation legend is embedded in the picture.
The mother lineage of proband 11, comprising all breast and ovarian cancer
patients is complete; some members of the father lineage of proband 11 are
not reported for lack of information. However, all significant cancer patients
from both lineages of up to three generations are reported.
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PCR-RFLP and SNapShot analysis. To detect the
c.190T>C (Cys64Arg) and c.2612C>T (Pro871Leu) variants
in BRCA1, and the c.-26G>A noncoding variant in BRCA2 in
Italian and Polish patients, i) PCR combined with restriction
fragment length polymorphism (RFLP) analysis, or ii)
SNaPshot techniques were used.
First, PCR products were amplified using 100-200 ng
DNA in a 25 μl reaction containing 0.5 mM dNTPs (Amersham
Bioscience), 1X PCR buffer (Invitrogen), 1.5 mM MgCl2
(Invitrogen), 1 mM forward and reverse primer (Invitrogen)
and 0.6 units Platinum Taq polymerase (Invitrogen). The
sequence of the primers used for each mutation or SNP can
be found in Table I.
The DNA fragment containing the Cys64Arg mutation
in BRCA1 was amplified using a 35-cycle PCR program
consisting of an initial denaturation step at 95˚C for 5 min,
35 cycles of 3 min with a denaturation step at 95˚C (1 min),
an annealing step at 58˚C (1 min), and an elongation step at
72˚C (1 min), followed by a final extension step of 10 min at
72˚C. After DNA amplification, PCR products were digested
(3 h at 37˚C) using the specific restriction endonuclease SnaB1
(New England Biolabs) which recognized and cut the variant
sequence. Digested products were analysed by gel electro-
phoresis on a 2% agarose gel and visualised under ultraviolet
light after ethidium bromide staining.
The PCR program for the c.2612C>T SNP (Pro871Leu)
in BRCA1 and the c.-26G>A SNP in BRCA2 consisted of an
initial denaturation step of 94˚C, 12 cycles of denaturation at
94˚C for 20 sec, annealing at 58˚C and elongation at 72˚C for
1 min. At each cycle, the annealing temperature decreased by
1˚C. This was followed by 24 cycles of 40 seconds at 94˚C,
40 sec at 46˚C and 30 sec at 72˚C and a final extension step at
72˚C (10 min). Further analyses used the SNapShot multiplex
system (Applied Biosystems); the SNapShot primers are
listed in Table I. Analyses of 2 μl of the SNaPshot product
with 10 μl Amresco capillary electrophoresis buffer (Lucron
Bioproducts) and 0.3 μl LIZ-120 size standard (Applied
Biosystems) was performed on the capillary system of an
ABI Prism 3730 genetic analyser (Applied Biosystems).
Results were visualised on the Peak scanner program version
1.0 (Applied Biosystems).
In silico structural and functional analysis of the Cys64Gly
mutation. The three-dimensional NMR structure of the
BRCA1-BARD1 RING finger heterodimer [PDB ID 1JM7;
(16)] was downloaded from the Protein data bank (http://www.
rcsb.org). Structural models were drawn with the Swiss-
PdbViewer (17).
Analysis of splice sites was performed using the
Information analysis tools at Schneider's lab, Molecular
Information Theory Group, Center for Cancer Research Nano-
biology Program, National Cancer Institute, Frederick, MD
(http://www.lecb.ncifcrf.gov/~toms/delila.html). Exonic
splicing enhancer analysis (18,19) was performed using the
ESEfinder 2.0 program, Cold Spring Harbor Laboratories
(http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?
process=home).
Immortalization of peripheral blood lymphocytes from patients
and healthy individuals. EBV-immortalized cell lines from
healthy individuals, homozygous (T/T) at the 109 locus, were
obtained from the cell bank of Professor A. Vral, (University
of Gent, Belgium). The EBV cell line BC1 was generated
from peripheral blood lymphocytes of the Italian patient 1
(Fig. 1), heterozygous for the c.190T>C mutation in BRCA1.
Immortalization was achieved by exposure of lymphocytes
to the supernatants of the B95-8 EBV producer cell line,
according to a standard protocol (20). EBV cell lines were
used to amplify transcript sequences of the BRCA1 gene by
RT-PCR, and for radiosensitivity testing with the cytokinesis-
block micronucleus (MN) assay, as previously described
(20). The EBV cell lines were maintained in RPMI-1640
medium supplemented with 10% fetal bovine serum, 2 mM
L-glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomycin
with 10% FBS and cultured at 37˚C, 5% CO2, in a humidified
incubator.
Analysis of BRCA1 transcripts by RT-PCR. Total RNA was
isolated from 107 EBV-immortalized lymphoblastoid cells
using the SV Total RNA isolation system (Promega Italy),
according to manufacturer directions. A 2-3 μg aliquot of
total RNA was used to generate first-strand cDNA and to
amplify transcript fragments with a RobusT II RT-PCR kit
(Finnzymes, Italy) at the following conditions: 48˚C for 30 min,
followed by 94˚C for 2 min for first-strand cDNA synthesis,
followed by 35 amplification cycles (94˚C, 30 sec; 60˚C,
60 sec; 72˚C, 1 min) and a final extension step at 72˚C for
7 min. To detect normal and/or alternative transcript fragments
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Table I. PCR primers for genotyping the c.190T>C (Cys64Arg) mutation in BRCA1, and SNaPshot primers for genotyping
the c.2612C>T (Pro871Leu) SNP in BRCA1 and the c.-26G>A SNP in BRCA2.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Mutation/polymorphism PCR primers SNaPshot primer
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
BRCA1: c.190T>C (Cys64Arg) F - GCCTTTTGAGTATTCTTTCTAC //
R - TCCTACTGTGGTTGCTTCC
BRCA1: c.2612C>T (Pro871Leu) F - GGAAGGCAAAAACAGAAC GTTTCAAAGCGCCAGTCATTTGCTC
R - CCAACCACAGGAAAGCCT
BRCA2: c.-26G>A F - TGTTACCTTCCAGGAGATG CATTTTTACCTACGATATTCCTCCAATG
R - AGCAACACTGTGACGTACTG
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
F, forward; R, reverse.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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of BRCA1, exon 5, we designed a forward primer (5'-ATT
TATCTGCTCTTCGCGTTG-3'), annealing with a specific
sequence on exon 5, and a reverse primer (5'-CACTGAG
ACTGGTTTCCTGC-3'), annealing on exon 6. In normal
conditions a fragment of 456 bp would be amplified by RT-
PCR. In case of alternative splicing, as described in cells
harboring the c.190T>C mutation (21), a 434-bp fragment
would be detected. For transcript fragment length analysis,
RT-PCR products were run on 2.5% agarose gels; fragments
were analyzed by restriction digestion (presence of T>C
mutation was screened with SnaBI) and automated sequencing.
Results and Discussion
Clinical and genetic analysis of the Italian HBOC pedigree.
Fig. 1 shows the HBOC pedigree from Italy analyzed in this
study. Patient 1 was born in 1931; at the age of 27 an undefined
‘adenomatous nodule’ was surgically removed from her left
breast. At age 47 she was diagnosed with bilateral breast
cancer; a right radical mastectomy and a left quadrantectomy
were performed to remove a T3N1b+ and a T1N0- lesion,
respectively; surgery was followed by chemotherapy. Ten
years later she was again hospitalized for removal of a left
T1N0- lesion by radical mastectomy. On the same occasion,
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Figure 2. (A) High-resolution melting analysis of exon 5 of BRCA1, shown
as a derivative plot (-dF/dT vs. temperature). Mutation c.190T>C is clearly
distinct from wild-type controls. (B) High-resolution melting analysis of
exon 5 of BRCA1, shown as difference plot (fluorescence vs. temperature),
compared to a known wild-type sequence. (C) Sequences of exon 5 of
BRCA1: the sample harboring c.190T>C is compared to a wild-type control.
The mutation is marked with an arrow.
Figure 3. Ribbon representation of the C3H zinc coordination site in the
BRCA1 N-terminal RING finger domain and of the BRCA1-BARD1
interaction interface (PDB ID: 1JM7). BRCA1 and BARD1 are shown in
green and blue, respectively. Sidechains of selected amino acids are
rendered in ball-and-stick representation. The wild-type protein is shown in
the top panel. The C3H site stabilizes the BRCA1-BARD1 interaction, with
a hydrogen bond between Asp40 of BRCA1 and Asn98 of BARD1. The
Zinc atom coordinated by the C3H structure, including Cysteine 64 and
Cysteine 61, is represented as a small sphere in color magenta. The bottom
panel shows the Cys64Arg mutant. Arginine 64 establishes a salt bridge
with Aspartic acid 67, with the consequent destabilization of the Zinc
coordination cage.
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diffuse ovarian dysplastic lesions were reported. The patient
underwent post-surgery standard chemotherapy treatment.
The patient is in long-term remission since 1989. Patient 2
was diagnosed with breast dysplasia over 15 years ago, and is
presently disease-free. Patient 3 was diagnosed with ovarian
cancer (pT N G2) in 1988 at the age of 58, underwent surgical
removal and chemotherapy, and is presently in remission.
Patients 1, 2 and 3 are daughters of patient 4, who died of
ovarian cancer at the age of 46. Patients 5 and 6, sister and
mother of patient 4, also died of ovarian cancer, both around
the age of 60.
All patients gave their informed consent for genetic analysis
and publication of anonymous data. Patient 1 gave her consent
for thorough BRCA1 and BRCA2 analysis. Genomic DNA was
purified from peripheral blood lymphocytes and subjected to
high-resolution melting analysis. Table II lists the mutations
and polymorphisms identified in this patient. The c.190T>C
mutation in exon 5 of BRCA1, generating the Cys64Arg amino
acid substitution, was detected (Fig. 2). Moreover, nine BRCA1
and four BRCA2 known sequence variants, detected with high
allele frequencies (19.57-38.26%) in diverse European control
populations (e.g., 23), were found. All sequence variants were
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Table II. Mutations and polymorphisms detected in the BRCA1 and BRCA2 genes in patient 1 from the Italian pedigree.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
BRCA1
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Nucleotide AA Sequence Times reported in BIC database,
Exon change change variant or literature reference
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
5 c.190T>C Cys64Arg Mutation 6
8 c.442-34C>T Intronic 9
11 c.2082C>T p= Synonymous 14
11 c.2311T>C p= Synonymous 25
11 c.2612C>T p.Pro871Leu Missense 26
11 c.3113A>G p.Glu1038Gly Missense 37
11 c.3548A>G p.Lys1183Arg Missense 33
13 c.4308T>C p= Synonymous 35
16 c.4956G>A p.Met1652Ile Missense 36
17 c.5074+65G>A Intronic Song et al (ref. 22)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
BRCA2
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Nucleotide AA Sequence
Exon change change variant Times reported in BIC database
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
2 c.-26G>A Non-coding 12
11 c.3396A>G p= Synonymous 8
11 c.3807T>C p= Synonymous 3
11 c.6841+80_83delTTAA Intronic 1
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Figure 4. Frequency distribution of micronucleus formation (number of micronuclei/500 binucleated cells) in 23 EBV-immortalized control cell lines
homozygous for the wild-type thymidine at position c.190 in the BRCA1 gene. The micronucleus score of the BC1 EBV-immortalized cell line (109±28
micronuclei/500 binucleated cells), homozygous for the c.190T>C mutation, is indicated with an arrow.
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cross-referenced with the Breast Cancer Information Core
(BIC; http://research.nhgri.nih.gov/projects/bic/) (Table II),
and all except two were classified as not clinically significant
by BIC. c.6841+80_83delTTAA was the only variant not
classified as non-significant; it is reported only once and
classified as unknown. This is not unusual, since it is located
80 bp away from exon junction, and the variants commonly
reported in BIC are up to 50 bp away from exon junctions.
This variant is present in a high percentage of healthy women
with no family history of breast cancer [allele frequency in a
central-European population: 38.26%; (23)], thus it can be
classified as non-significant.
Together with the missense Cys64Gly substitution,
Cys64Arg is listed as being of unknown clinical significance
in the BIC database. However, the Cys64Tyr substitution is
defined as clinically important.
The functional relevance of the Cys64Arg substitution is
described in the following section. Analysis of the poly-
morphisms detected in patient 1, showed the presence of the
c.2612C>T (Pro871Leu) missense polymorphism in BRCA1,
and of the c.-26G>A noncoding variant in BRCA2 (Table II).
The significance of these mutations will be discussed in the
following chapter.
Structural and functional analysis of the c.190T>C missense
mutation
Functional role of the Cys64Arg amino acid substitution.
Cys61Gly and Cys64Gly are among the most prevalent
BRCA1 missense mutations, and are hypothesized to be
responsible for hereditary breast cancer. These substitutions
target specific metal-binding residues of BRCA1, and alter
zinc coordination within the RING domain by presumably
disrupting its three-dimensional coordination and in turn
resulting into the impairment of BRCA1 interaction with its
major functional ligand, BARD1 (reviewed in ref. 5).
The Cys61Gly mutation was shown to abolish metal
binding to Site II of the RING domain of BRCA1, and disrupt
BRCA1 homodimer formation (24). Moreover, the mutation
resulted in increased proteolytic susceptibility of the carboxy-
terminal portion of the amino-terminal domain of BRCA1.
The Cys61Gly mutation was also shown to abolish the in vitro
ubiquitin-ligase activity displayed by the BRCA1-BARD1
complex (25).
The Cys64Gly mutation was demonstrated in a large
African-American pedigree, characterized by early-onset
breast/ovarian cancer, and subsequently in other African-
American families (1). Similarly to Cys64Gly and Cys61Gly,
the Cys64Tyr mutation was shown to abolish the ubiquitin
protein kinase activity of BRCA1, and to cause hypersensitivity
to ionizing radiation (26). The same role can be hypothesized
for the more rare Cys64Lys mutation (27)
So far, the Cys64Arg mutation has only been reported in
Italy and in a single unrelated family in Poland (15,28,29).
Similarly to Cys61Gly, Cys64Gly and Cys64Tyr (26), the
Cys64Arg substitution may cause disruption of BRCA1-
BARD1 interactions, thus affecting the ubiquitin-ligase
activity of this heterodimeric complex.
The N-terminal region of BRCA1 shows the typical
RING finger structure, belonging to the C3HC4 RING finger
domain family. In this family, two zinc ions are tetrahedrally
coordinated by three cysteines and one histidine residue, and
by four cysteine residues, respectively (see Fig. 3, upper panel,
for a model). BRCA1 and BARD1 interact via an extensive
anti-parallel 4-helix bundle interface formed by helices that
flank the central RING motifs. From the analysis of the NMR
structure of the BRCA1-BARD1 RING finger heterodimer
(PDB ID: 1JM7), it appears that the Cys64 residue, belonging
to the C3H Zn coordination motif, is in close proximity to the
Asp67 residue on the beta strand flanking the Zn environment.
In the case of the Cys64Arg mutation, Arg64 is able to rotate
towards Asp67, possibly forming a salt bridge (Fig. 3, lower
panel). In turn, Zn is no longer stabilized by the tetrahedral
coordination field formed by Cys39, His41, and Cys61.
Alternatively, the Zn ion might form a complete coordination
cage involving the Arg64 Nε atom. Interestingly, in the wild-
type protein the beta strand opposite to the mutation (e.g.,
Cys39, Asp40, and His41) interacts with BARD1, with a
hydrogen bond between Asp40 of BRCA1 and Asn98 of
BARD1 (Fig. 3). It might therefore be suggested that the
Cys64Arg mutation determines a rearrangement of the
BRCA1 39-41 residues and destabilizes the BRCA1(Asp40)-
BARD1(Asn98) interaction (Fig. 3).
A similar hypothesis for the destabilization of the complex
can be formulated for the Cys64Gly and Cys64Tyr mutants,
described in other BRCA1 pedigrees (24-26). In the first case,
the zinc atom should clearly dissociate from its coordination
site. In the latter case, Tyr does not appear to be able to rotate
towards the Zn ion, unless a dramatic rearrangement of the
BRCA1 39-41 strand would take place.
BRCA1 involvement in DNA double-strand break repair.
By likely disrupting the RING domain binding capacity, the
Cys64Arg substitution might decrease the capacity of BRCA1
to stimulate DNA double-strand break repair in response to
genotoxic agents such as ionizing radiation. This was shown
for the Cys64Gly, Cys64Tyr and Cys61Gly substitutions (26).
To test this hypothesis, we generated an EBV-immortalized
lymphoblastoid cell line from peripheral blood lymphocytes of
patient 1 from the Italian HBOC family, denominated BC1.
Since BC1 cells showed an unexpected loss of heterozy-
gosity during immortalization (Fig. 6, under investigation),
they represented an optimal model for unbiased analysis of
DNA DSB repair capacity. Cells were exposed to a dose of
2-Gy Á-rays, and subjected to the cytokinesis-block micro-
nucleus (MN) assay. Radiosensitivity of BC1 cells (109±28
micronuclei/500 binucleated cells) was compared to radio-
sensitivity of 23, randomly selected control EBV cell lines,
T/T homozygous at locus 190 (codon 64). Fig. 4 shows the
frequency distribution of MN scores of control EBV cell lines.
Sixteen cell lines were more resistant to the genotoxic
damage of ionizing radiation, whereas only 7 EBV control cell
lines were found to be more radiosensitive. Thus, BC1 cells,
carriers of the homozygous c.190T>C mutation, were
amongst the most radiosensitive cell lines investigated.
Effect of the c.190T>C mutation on BRCA1 mRNA splicing.
The c.190T>G mutation was shown to generate aberrant
splicing products of the BRCA1 RNA (21). This occurred by
two main mechanisms. First, the T>G transversion activated
a cryptic splicing donor site located within the coding region
of exon 5, adjacent to the boundary with intron 5. Activation
of the cryptic splicing donor site in the T>G mutant results in
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Figure 5. (a) Lister map, sequence walkers and information content of
natural and cryptic splice donors of BRCA1 exon 5. Exonic sequences are
capitalized. (A) information content of the natural splicing donor (in dark
grey). The position of the cryptic splicing donor is highlighted in light grey.
(B) information content of the cryptic splicing donor (in light grey), in the
absence of an activating mutation. The c.190T base is represented in dark
grey. (C) cryptic splicing donor (in light grey) activated by the c.190T>G
transversion (in dark grey). (D) putative cryptic splicing donor containing
the c.190T>C mutation (in dark grey). The Schneider's lab tools (http://www.
lecb.ncifcrf.gov/~toms/delila.html) were used to produce lister map and
sequence walkers, and to calculate the information content of these splicing
sites. (b) Effect of the c.190T>G and c.190T>C mutations on high-score
SRp55-binding motifs, in BRCA1 exon 5. SR motif analysis was performed
using ESEfinder (http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?
process=home). The c.190T>G mutation results in disruption of the SRp55
motif shown by the arrow. Conversely, the c.190T>C mutation increases the
score of the SRp55 motif from ~3.6 to ~5.1. SR motif types are listed in the
legend.
a
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the deletion of 22 bases from exon 5, and in the generation of
an aberrant, frame-shifted transcript, predicted to create an
UGA premature termination codon at position 80 within
exon 6 (21).
Surprisingly, in addition to the activation of a cryptic
splicing site, the c.190T>G mutation was shown to disrupt a
high-score SRp55-binding exonic splicing enhancer (ESE)
motif (position 189-193), likely involved in the normal splicing
mechanism of intron 5 (21).
To investigate the influence of the c.190T>C mutation in
BRCA1 splicing, we compared by information analysis the
information content (IC) of the natural BRCA1 exon 5
splicing donor with the corresponding value of the putative
splicing sites generated by the c.190T>G and c.190T>C
mutations.
Fig. 5 shows that the natural splicing donor of BRCA1
exon 5 is characterized by an information content (IC) of 6.0
bits. Interestingly, the wild-type cryptic donor (c.190T), located
22 bases upstream the exon 5-intron 5 boundary, shows a
slightly higher information content (6.2 bits, Fig. 5a). The
choice of the natural splicing donor over the cryptic one, is
likely determined by the presence of splicing modulators,
like the SRp55 motif described above, disrupted by the
c.190T>G mutation (21).
In the presence of the c.190T>G mutation, the score
of the cryptic splice donor increases markedly, to a value of
9.5 bits. Since the likelihood of a splicing event has been
shown to correlate with the amount of information contained
in competing, alternative splice sites (30), our information-
content analysis confirms the data described by Yang and
coworkers (21), and shows that the c.190T>G mutation, by
increasing the IC of a cryptic splice donor, is responsible for
the generation of alternatively-spliced, aberrant transcripts
of the BRCA1 gene.
In striking contrast with this evidence, information analysis
showed that the c.190T>C mutation decreases the information
content of the cryptic splicing donor from 6.2 to a value of
5.5 bits, thus diminishing the likelihood of aberrant splicing
of the BRCA1 RNA.
This hypothesis was strongly supported by analysis of
the ESE motifs likely concurring to exon 5 splicing. Fig. 5b
shows that, as shown by Yang et al (21), the c.190T>G
mutation results in disruption of a high-score SRp55-binding
ESE motif. However, the c.190T>C mutation not only
preserves the binding capacity of the ESE motif, but also
further increases its score from ~3.6 to ~5.1.
In summary, whereas the c.190T>G mutation increases
the information content of the competing, cryptic splice site
located 22-nt upstream of the natural donor of exon 5, and
simultaneously disrupts a high-score SRp55 binding site,
working in normal conditions to the advantage of normal
splicing of intron 5, the c.190T>C mutation preserves and even
strengthens the natural splicing scenario of BRCA1 intron 5,
by decreasing the information content of the cryptic splice
donor, and concurrently increasing the strength of the SRp55
ESE motif.
To confirm these in silico data, we analyzed by RT-PCR
the splicing pattern and transcript sequence of the exon
5-exon 6 boundary, using total RNA purified from the BC1
mutant cell line. RT-PCR performed with the same primers,
annealing with specific sequences in exon 5 and exon 6, used
by Yang et al in their splicing study (21), yielded the expected
fragment of 456 bp (Fig. 6). The experiment was repeated
6 times with varying stringency conditions, but no fragments
indicative of aberrant splicing were detected. Sequencing of
the 456-bp PCR fragment amplified from BC1 cells confirmed
a correct splicing pattern of BRCA1, at the level of exons 5
and 6 (Fig. 6).
Possible role of single nucleotide polymorphisms in BRCA1
and BRCA2, in the generation of the phenotype observed in the
Italian HBOC family. In the literature, the typically Italian
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Figure 6. The c.190T>C missense mutation in BRCA1 exon 5 does not result
in aberrant splicing, as shown by the presence of a 456-bp fragment,
generated by RT-PCR with primers annealing with specific sequences in
exons 5 (forward primer) and 6 [reverse primer; for primer sequences, see
Materials and methods and (21)]. Lane 1: HindIII digest DNA marker;
Lanes 2-4: EBV-immortalized, c.190T-homozygous cell lines from 3
control healthy individuals (selected randomly from the collection of 23
lines described in Materials and methods). Lanes 5 and 6: EBV-
immortalized BC1 cell line from patient 1 (Italian pedigree). The small 200-
bp fragment shown in lane 6 was sequenced, and represented a nonspecific
amplicon. Lane 7: 100-bp marker. Template RNA was purified from BC1
cells, harboring the heterozygous c.190T>C mutation. Correct junction of
exon 5 and exon 6 extremities in a BRCA1 transcript from BC1 cells,
confirmed by sequencing of the 456-bp fragment purified from this gel, is
shown in the electropherogram.
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c.190T>C mutation has to our best knowledge only been
reported abroad in Poland, in a large family without Italian
ancestry (15). This family is characterized by 3 cases of breast
cancer (with two long-term survivors), one case of ovarian
cancer (deceased) and one case of leukemia in a male proband
(Fig. 7). For tentative comparison with a pedigree showing a
potentially unrelated haplotype, we analyzed a total of 8
healthy or diseased probands from this Polish family.
As shown in a previous paragraph, analysis of the BRCA1/
BRCA2 genotype of patient 1 from the Italian HBOC family
(Table II), showed the presence of two heterozygous
polymorphisms that were reported in the literature to be
significantly linked to breast or ovarian cancer.
c.2612C>T, BRCA1. The c.2612C>T missense variant in
exon 11 of BRCA1, responsible for the Pro871Leu amino
acid substitution, was shown to be the only polymorphic
variant, out of a panel of 19 SNPs detected in BRCA1, whose
frequency was significantly higher in patients (42%) than in
control individuals (28%) (31). This was described in a
population of 200 patients with breast/ovarian cancer
screened for BRCA1 mutations, drawn primarily from high-
risk families and from isolated early-onset breast cancer
cases. Comparison was made with a population of control
individuals of diversified haplotypes.
Interestingly, the heterozygous c.2612C>T transition was
detected in patients 1 and 3 from the Italian pedigree, but not
in the cancer-free proband 2 (Table III), sister of these two
patients. In breast cancer patients 7 and 8 from the Polish
pedigree, the Pro871Leu substitution was found in a hetero-
zygous and homozygous expression, respectively (Table III).
All other healthy younger family members express this
mutation in homo- or heterozygous forms. It would be of
interest to extend these observations to larger patient
populations and pedigrees, to ascertain the role of this poly-
morphism in the phenotypical expression of neoplasia (age of
onset, intra-pedigree prevalence, penetrance and influence on
prognosis).
c.-26G>A, BRCA2. It has been demonstrated that the risk of
ovarian cancer is higher for carriers of BRCA1 mutations in
the 5' portion of the gene, (e.g., Cys64Arg), although larger
excesses of ovarian cancers were also observed near the 3'-end
of the gene (32). In Italian patients carrying the Cys64Arg
mutation, the ratio between breast and ovarian lesions was
shown to be ~10-fold (28). In contrast, the Italian HBOC
pedigree analyzed in this study showed a high prevalence of
ovarian cancers (80%; Fig. 1). Moreover, in breast cancer
patient 1, ovarian precancerous lesions were detected. In
families showing highly predominant ovarian lesions, the
presence of modifier factors influencing the tumor localization
may be hypothesized.
The c.-26G>A transition within the 5'UTR of BRCA2 was
initially identified as a polymorphism able to suppress the
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Table III. Expression of significant polymorphisms in the
BRCA1 or BRCA2 genes, in Italian and Polish pedigrees.a
–––––––––––––––––––––––––––––––––––––––––––––––––
Pedigree Pt. no. BRCA1, c.2612C>T BRCA2, c.-26G>A
–––––––––––––––––––––––––––––––––––––––––––––––––
Italy 1 C/T G/A
2 C/C G/G
3 C/T G/A
Poland 7 C/T G/G
8 T/T G/G
12 C/T A/A
14 C/T G/G
15 C/T G/G
20 C/T G/A
29 T/T G/G
64 T/T G/A
–––––––––––––––––––––––––––––––––––––––––––––––––
aCancer patients are emphasized with bold italic fonts.
–––––––––––––––––––––––––––––––––––––––––––––––––
Figure 7. Pedigree of a Polish family characterized by prevalent breast neoplasms in carriers of the c.190T>C mutation. BrC, breast cancer; Leu, leukemia;
Col, colon cancer; OvC, ovarian cancer; mut, mutation carrier.
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expression of the RNA transcribed from its carrier allele,
without affecting transcription of the allele carrying the c.-26G
variant (33). This allele-specific BRCA2 suppression was
demonstrated only in patients harboring a pathogenic mutation
in BRCA2, and not in individuals heterozygous for the
c.-26G>A SNP, but lacking an additional deleterious
mutation (33).
The c.-26G>A polymorphism in BRCA2 was subsequently
characterized as an ovarian cancer risk modifier in carriers
of deleterious BRCA1 mutations. In a study performed on 778
women carrying a BRCA1 germline mutation belonging to
403 families, a significant association of the c.-26A allele with
increased risk of ovarian cancer was observed (Hazard ratio:
1.43, 1.01-2.00, 95% CI) (34). The authors postulated for the
c.-26G>A variant of BRCA2 a role as modifier of BRCA1-
associated ovarian cancer risk in BRCA1-mutation carriers,
but not in the general population (34).
In the Italian pedigree shown in Fig. 1, characterized by
predominant ovarian lesions, heterozygous expression of the
c.-26G>A polymorphism was documented in cancer patients
1 and 3, showing bilateral breast cancer and diffuse ovarian
dysplasia, and ovarian cancer, respectively (Table III). Cancer-
free proband 2, sister of patients 1 and 2, shows a homozygous
G/G genotype. Interestingly, the patients of the Polish
pedigree (Fig. 7), characterized by predominant breast cancers,
showed a homozygous G/G profile.
In summary, the c.2612C>T and the c.-26G>A common
variants seem to segregate in the Italian and Polish pedigrees
in a fashion coherent with their hypothetic role. However, the
data shown in this study, analyzed in only two pedigrees, are
only indicative of the potential association of the studied
polymorphisms with disease penetrance and phenotypical
modulation. It would be of interest to substantiate these
preliminary observations with extensive studies performed
on a large number of related and unrelated pedigrees.
In conclusion, the c.190T>C (Cys64Arg) mutation
analyzed in this study is presently described in the BIC
database as a mutation of unknown clinical significance. Our
study is indicative of a pathogenic role of this mutation, as
shown in a preliminary survey of two unrelated familial breast
and ovarian cancer pedigrees. In vitro and in silico functional
experiments and observations indicate that the c.190T>C
mutation may induce profound modifications in the structure
of the BRCA1 RING finger, but, unlike the Cys64Gly
substitution, without affecting the normal splicing pattern of
the BRCA1 transcript. Additional polymorphic variants,
shown in the literature to be associated with disease
penetrance or ovarian cancer risk modulation, might have
concurred to the peculiar phenotypic characteristics of the
pedigrees examined in this preliminary study.
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